What is Angioblasts relationship with Mesoblast?
In 2004 Mesoblast had an IPO and committed to invest AUS$10,000,000 (in milestone-linked tranches) into Angioblast for a 33% equity interest in Angioblast. Angioblast and Mesoblast have and will continue to share certain costs relating to pre-clinical and clinical development, patent management and technology development. Angioblast was assigned all intellectual property for MPC-related discoveries from the Institute of Medical and Veterinary Science and the Hanson Institute in South Australia , covering composition of matter and enablement of MPCs. Mesoblast has a worldwide exclusive license for the use of MPCs in all orthopedic applications, and Angioblast has such a license for all other applications.
